Loading
A phase 3 trial of Darolutamide in prostate cancer, run by Bayer, active and no longer recruiting.
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies is a phase 3 interventional study registered as NCT05794906 by Bayer, with 985 participants enrolled, started 2023-04-03 and due to reach its primary completion in 2027-07-30. Interventions recorded: Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT. Conditions listed: Biochemically Recurrent Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darolutamide, Bayer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Bayer, Androgen deprivation & AR pathway inhibitors.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Biochemical recurrence of prostate cancer, Prostate cancer.
Shares Biochemical recurrence of prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/